Biontech Se ADR (BNTX) Stock Price, Quote & News

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 6131 9084

Fax: 49 6131 9084

Website: www.biontech.de

Address:

An der Goldgrube 12, Mainz, Germany

wahoowa96 Aug. 30 at 1:41 PM

$ARCT $BNTX $MRNA Moderna cancer vaccines successful in phase 3 recently was comination therapy setup. What BioNTech is terminating is mRNA based vaccines alone monotherapy in Colon cancer...but they are still keeping the mRNA based cancer vaccines in combination therapy (along with chemo or checkpoint inhibitors).

2 · Reply

Samishere Aug. 30 at 5:28 AM

$BNTX

0 · Reply

wahoowa96 Aug. 29 at 11:04 PM

$ARCT $BNTX $MRNA I am reading the patient recruits for the colorectal cancer were in stage 2 and 3 and tumor cells were circulating in the body. But the pancreatic cancer seems to be going well.

1 · Reply

Crivit Aug. 29 at 8:56 PM

$BNTX 🔜 $NVAX

1 · Reply

None_ Aug. 29 at 6:55 PM

$BNTX https://www.statnews.com/2022/05/10/it-took-years-but-the-failure-and-futility-of-northwest-bios-brain-cancer-vaccine-is-now-in-the-open/

0 · Reply

ILuvbiotech Aug. 29 at 3:28 PM

$BNTX investors following personalised cancer vaccines should take a look at $NWBO . DCVax-L takes a completely different approach from mRNA, using a patient's own tumour material to create a personalised dendritic-cell vaccine. The Phase 3 trial has already reported results and the programme is now at the regulatory stage. Interesting space to compare.

3 · Reply

eightytwentie Aug. 28 at 6:28 PM

$BNTX futility boundary for BNT122 was actually crossed in Sept 2025, so this was really no surprise

0 · Reply

IntelInjection Aug. 28 at 5:29 PM

$BNTX $MRNA the melanoma phase 2 data was about patients who have mild tumor mole removed, not for people who had a real tumor, that’s why it “looked good”. This tech has failed and will have no impact on cancer. Stop dreaming.

1 · Reply

StocktwitsNews Aug. 28 at 5:22 PM

BNTX Stock On Track For Worst Day Since March After Cancer Vaccine Trial Halt — BMO Capital Terms It ‘Clear Setback’ $BNTX $MRNA https://stocktwits.com/news/equity/markets/bntx-stock-on-track-for-worst-day-since-march-after-cancer-vaccine-trial-halt-bmo-capital-terms-it-clear-setback/cZYALnJRJAs

0 · Reply

pb_syr Aug. 28 at 4:08 PM

$BNTX The Moderna run up for $BNTX is fading now that their cancer vax trial failed

1 · Reply

BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why

MRK MRNA

2026-08-28T16:10:13.000Z - 2 days ago

Cevumeran trial termination a ‘clear setback’ for BioNTech, says BMO Capital

2026-08-28T14:55:25.000Z - 2 days ago

mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley

MRK MRNA

Aug 28, 2026, 9:41 AM EDT - 2 days ago

BioNTech to terminate mid-stage trial of mRNA cancer vaccine

2026-08-28T13:20:17.000Z - 2 days ago

BioNTech drops 9% after ending Phase 2 colorectal cancer trial

2026-08-28T13:10:11.000Z - 2 days ago

BioNTech to terminate Phase 2 monotherapy trial of cevumeran

Aug 27, 2026, 5:48 PM EDT - 2 days ago

US FDA approves updated COVID vaccines for 2026-27 season

MRNA NVAX PFE SNY

2026-08-27T20:35:15.000Z - 3 days ago

Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine

PFE

Aug 27, 2026, 4:30 PM EDT - 3 days ago

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

PFE

Aug 20, 2026, 5:30 AM EDT - 10 days ago

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

2026-08-19T16:05:37.000Z - 11 days ago

BioNTech rises 20.3%

2026-08-19T14:00:12.000Z - 11 days ago

BioNTech rises 21.6%

2026-08-05T14:23:35.000Z - 25 days ago

BioNTech price target lowered to $130 from $135 at Evercore ISI

2026-08-05T11:05:37.000Z - 25 days ago

BioNTech price target raised to $142 from $138 at Canaccord

2026-08-05T10:35:32.000Z - 25 days ago

BioNTech price target lowered to $125 from $130 at Citi

Aug 4, 2026, 8:00 AM EDT - 26 days ago

BioNTech SE Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 26 days ago

BioNTech SE Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 26 days ago

BioNTech SE Slides: Q2 2026

Aug 4, 2026, 7:12 AM EDT - 26 days ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

PFE

Aug 4, 2026, 7:02 AM EDT - 26 days ago

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

2026-08-04T10:50:25.000Z - 26 days ago

BioNTech cuts FY26 revenue view to EUR 1.6B-EUR 1.9B from EUR 2B-EUR 2.3B

Aug 4, 2026, 6:45 AM EDT - 26 days ago

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

Aug 3, 2026, 5:29 AM EDT - 27 days ago

BioNTech says Sobi's Oelkers will replace Sahin as CEO

Aug 3, 2026, 5:00 AM EDT - 27 days ago

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

Jul 29, 2026, 4:30 PM EDT - 4 weeks ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

PFE

Jul 21, 2026, 6:45 AM EDT - 5 weeks ago

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

Jul 3, 2026, 1:51 AM EDT - 2 months ago

BioNTech held buyer talks over four German sites set to close, Handelsblatt reports

Jun 17, 2026, 2:38 AM EDT - 2 months ago

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

MRNA

May 30, 2026, 2:15 PM EDT - 3 months ago

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

May 27, 2026, 11:07 AM EDT - 3 months ago

This Biotech's Cancer Portfolio Could End Its Rough Patch

May 22, 2026, 5:00 AM EDT - 3 months ago

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

May 15, 2026, 4:15 PM EDT - 3 months ago

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

May 15, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Transcript: AGM 2026

May 7, 2026, 6:45 AM EDT - 4 months ago

BioNTech Announces New ADS Repurchase Program

May 6, 2026, 7:44 AM EDT - 4 months ago

Germany says vaccine supply secure despite BioNTech production loss

May 5, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Slides: Q1 2026

May 5, 2026, 7:26 AM EDT - 4 months ago

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

May 5, 2026, 6:47 AM EDT - 4 months ago

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

May 5, 2026, 6:45 AM EDT - 4 months ago

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Apr 21, 2026, 5:35 PM EDT - 4 months ago

Two experimental drugs showed striking early results against pancreatic cancer

RVMD

Apr 21, 2026, 6:45 AM EDT - 4 months ago

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

Apr 11, 2026, 7:00 AM EDT - 5 months ago

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Apr 1, 2026, 11:39 AM EDT - 5 months ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

Mar 24, 2026, 6:45 AM EDT - 5 months ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 10, 2026, 2:48 PM EDT - 6 months ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 1:29 PM EDT - 6 months ago

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Slides: Q4 2025

Mar 10, 2026, 7:40 AM EDT - 6 months ago

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:18 AM EDT - 6 months ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 6:50 AM EDT - 6 months ago

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:49 AM EDT - 6 months ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:45 AM EDT - 6 months ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:33 AM EDT - 6 months ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Feb 24, 2026, 6:45 AM EST - 6 months ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 19, 2026, 1:25 PM EST - 6 months ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

Jan 28, 2026, 8:00 AM EST - 7 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 13, 2026, 5:15 PM EST - 8 months ago

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 8 months ago

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 8 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 10:00 AM EST - 8 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Dec 18, 2025, 4:45 AM EST - 9 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 9, 2025, 7:00 AM EST - 9 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

Dec 6, 2025, 3:30 PM EST - 9 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 3, 2025, 9:01 AM EST - 9 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

Dec 1, 2025, 3:50 PM EST - 9 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Dec 1, 2025, 12:35 PM EST - 9 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

Nov 26, 2025, 7:30 AM EST - 9 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 13, 2025, 5:20 PM EST - 10 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Nov 13, 2025, 8:17 AM EST - 10 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Slides: R&D Day

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Slides: Q3 2025

Nov 3, 2025, 6:47 AM EST - 10 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

wahoowa96 Aug. 30 at 1:41 PM

2 · Reply

Samishere Aug. 30 at 5:28 AM

$BNTX

0 · Reply

wahoowa96 Aug. 29 at 11:04 PM

$ARCT $BNTX $MRNA I am reading the patient recruits for the colorectal cancer were in stage 2 and 3 and tumor cells were circulating in the body. But the pancreatic cancer seems to be going well.

1 · Reply

Crivit Aug. 29 at 8:56 PM

$BNTX 🔜 $NVAX

1 · Reply

None_ Aug. 29 at 6:55 PM

$BNTX https://www.statnews.com/2022/05/10/it-took-years-but-the-failure-and-futility-of-northwest-bios-brain-cancer-vaccine-is-now-in-the-open/

0 · Reply

ILuvbiotech Aug. 29 at 3:28 PM

3 · Reply

eightytwentie Aug. 28 at 6:28 PM

$BNTX futility boundary for BNT122 was actually crossed in Sept 2025, so this was really no surprise

0 · Reply

IntelInjection Aug. 28 at 5:29 PM

1 · Reply

StocktwitsNews Aug. 28 at 5:22 PM

0 · Reply

pb_syr Aug. 28 at 4:08 PM

$BNTX The Moderna run up for $BNTX is fading now that their cancer vax trial failed

1 · Reply

NX19 Aug. 28 at 3:49 PM

$BNTX

0 · Reply

Nganlm Aug. 28 at 3:36 PM

$ARCT https://finance.yahoo.com/healthcare/articles/biontech-drops-10-mrna-trial-140949234.html This is related to BionTech. $BNTX $MRNA

0 · Reply

htw7448 Aug. 28 at 2:46 PM

$BNTX only some days ahead of major readouts this stock price is a gift for investors on the sideline. Conference is starting on 11 th September.

0 · Reply

cubie Aug. 28 at 2:35 PM

$MRNA $CRWD $PANW $BNTX didn't help moderna

2 · Reply

Vanilla_Coffee_Time Aug. 28 at 2:19 PM

$BNTX I just came to see if anyone is even bullish on this news Thankfully a lot more intelligent people in here than over at clot shot Moderna chat board

0 · Reply

notreload_ai Aug. 28 at 2:11 PM

$BNTX stops autogene cevumeran in resected, ctDNA-positive colorectal cancer after a DSMB survival imbalance. No new safety issues found. https://notreload.xyz/xy/biontech-ends-phase-2-mrna-vaccine-trial-in-crc/

0 · Reply

CheckingMorons Aug. 28 at 1:59 PM

$BNTX wow it went to 96 imagine buying that dip so lucky bastards

0 · Reply

AIIAAIIA_88 Aug. 28 at 1:40 PM

$BNTX Colorectal cancer was the most difficult for mRNA therapy. It was somewhat expected. But mRNA therapy for skin and lung cancers are almost guaranteed to succeed. Then there are pancreatic cancer which only BNTX currently is trying. Other cancers such as prostate, liver, kidney, stomach also have a decent chance. BNTX and even MRNA are cheap, given the potentials. Know what you long or short. JMO

0 · Reply

kindness123 Aug. 28 at 1:30 PM

$BNTX $MRNA

0 · Reply

hunanddone Aug. 28 at 1:18 PM

$BNTX

0 · Reply

green_going_up Aug. 28 at 1:17 PM

$BNTX halted a trial; firm has not been able to really gain traction using its mRNA platform outside of COVID; originally, I was surprised that $PFE - it's partner in COVID - didn't acquire BNTX and decided to develop its own mRNA platform. Pfizer clearly viewed that BNTX's mRNA platform - while useful in COVID - was not as robust of an mRNA platform as it could develop on its own. That has since been shown in cancer trials to date; BNTX's mRNA platform clearly lags that of $MRNA

2 · Reply

IjustTradeiT Aug. 28 at 1:13 PM

$BNTX What a great short on that mRNA pump

0 · Reply

Market Cap	28.17B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.29B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.59%
Debt to Equity Ratio	0.02

Volume	3,072,800
Avg Vol	1,222,632
Day's Range	N/A - N/A
Shares Out	252.88M
Stochastic %K	38%
Beta	1.27
Analysts	Strong Sell
Price Target	$123.67